Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple sclerosis drug Tysabri were immediate and dramatic, it could have long-term consequences on the whole class of drug as companies developing drugs with a similar mechanism of action as Tysabri had to suspend their trials.
For the past 40 years, there has been no major addition to the repertoire of drugs for treating severe, chronic pain. Now, two drugs with a completely different mechanism of action, targeting N-type calcium channels, are making their market debuts in the US and Europe—milestones that have received remarkably little attention.
Australia's biotech sector has no shortage of good ideas with a total of 30 new companies listing on ASX over the past 20 months. But with too many immature companies, and not enough sophisticated investors, the sector is struggling to achieve stability and growth.
Monsanto recently acquired a US fruit and vegetable seed outfit, a move that both Wall Street analysts and environmental activists (oddly) agree could spell trouble.
Veterinarian Lester Crawford has been nominated to be Commissioner of the US Food and Drug Administration. Can he provide the agency with the leadership it so desperately needs?
Surging numbers of therapeutic proteins and small molecules, rationally designed to trigger cell death, are entering the clinic against cancer. In theory, they should provide an entirely new kind of targeted therapy, but troubling questions of basic biology remain.
A lesser known valuation approach for biopharmaceutical products offers project managers and out-licensing biotech companies an edge in budget and license negotiations.